Evidence map›Paper›PMID 39765793›Full record

ArticleAntioxidants (Basel, Switzerland)2024

Association Between Oxidative Potential of Particulate Matter Collected by Personal Samplers and Systemic Inflammation Among Asthmatic and Non-Asthmatic Adults.

Miguel Santibáñez, Juan José Ruiz-Cubillán, Andrea Expósito, Juan Agüero, Juan Luis García-Rivero, Beatriz Abascal, Carlos Antonio Amado, Laura Ruiz-Azcona, Marcos Lopez-Hoyos, Juan Irure and 6 more

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Miguel SantibáñezGlobal Health Research Group, Faculty of Nursing, Universidad de Cantabria-Valdecilla Research Institute (IDIVAL), Avenida Valdecilla, s/n, 39008 Santander, Cantabria, Spain.
Juan José Ruiz-CubillánDivision of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39008 Santander, Cantabria, Spain.ORCID 0000-0002-7251-0232
Andrea ExpósitoDepartamento de Ingenierías Química y Biomolecular, Universidad de Cantabria, Avenida Los Castros, s/n, 39005 Santander, Cantabria, Spain.ORCID 0000-0002-5465-5913
Juan AgüeroDivision of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39008 Santander, Cantabria, Spain.
Juan Luis García-RiveroDivision of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39008 Santander, Cantabria, Spain.
Beatriz AbascalDivision of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39008 Santander, Cantabria, Spain.
Carlos Antonio AmadoDivision of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39008 Santander, Cantabria, Spain.ORCID 0000-0002-5598-1753
Laura Ruiz-AzconaGlobal Health Research Group, Faculty of Nursing, Universidad de Cantabria-Valdecilla Research Institute (IDIVAL), Avenida Valdecilla, s/n, 39008 Santander, Cantabria, Spain.ORCID 0000-0003-2213-2728
Marcos Lopez-HoyosDivision of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39008 Santander, Cantabria, Spain.ORCID 0000-0003-0562-427X
Juan IrureDivision of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39008 Santander, Cantabria, Spain.ORCID 0000-0003-2315-8671
Yolanda RoblesDivision of Biochemistry, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39008 Santander, Cantabria, Spain.
Ana BerjaDivision of Biochemistry, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39008 Santander, Cantabria, Spain.
Esther BarreiroPulmonology Department-Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer, IMIM-Hospital del Mar, Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra, Barcelona Biomedical Research Park (PRBB), 08003 Barcelona, Spain.
Adriana Núñez-RobainasPulmonology Department-Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer, IMIM-Hospital del Mar, Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra, Barcelona Biomedical Research Park (PRBB), 08003 Barcelona, Spain.ORCID 0000-0002-5891-5022
José Manuel CifriánDivision of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39008 Santander, Cantabria, Spain.ORCID 0000-0003-3682-0142
Ignacio Fernandez-OlmoDepartamento de Ingenierías Química y Biomolecular, Universidad de Cantabria, Avenida Los Castros, s/n, 39005 Santander, Cantabria, Spain.

Funding

Sociedad Española de Neumología y Cirugía Torácica SEPAR Nº 1383/23; Nº 1616/24Spanish Ministry of Science and Innovation Project PID2020-114787RBI00, MCIN/AEI/10.13039/501100011033
6 · The paper itself

Abstract

With the rationale that the oxidative potential of particulate matter (PM-OP) may induce oxidative stress and inflammation, we conducted the ASTHMA-FENOP study in which 44 asthmatic patients and 37 matched controls wore a personal sampler for 24 h, allowing the collection of fine and coarse PM fractions separately, to determine PM-OP by the dithiothreitol (DTT) and ascorbic acid (AA) methods. The levels of Interleukin 6 (IL-6) and the IL-6/IL-10 ratio, as indicators of pro- and anti-inflammatory statuses, were determined by calculating the mean differences (MDs), odds ratios (ORs) and p-trends adjusted for sex, age, study level and body mass index. Positive associations for IL-6 levels in the form of adjusted MDs and ORs were obtained for all PM-OP metrics, reaching statistical significance for both OP-DTT and OP-AA in the fine fraction, with adjusted OR = 5.66; 95%CI (1.46 to 21.92) and 3.32; 95%CI (1.07 to 10.35), respectively, along with statistically significant dose-response patterns when restricting to asthma and adjusted also for clinical variables (adjusted p-trend = 0.029 and 0.01). Similar or stronger associations and dose-response patterns were found for the IL-6/IL-10 ratio. In conclusion, our findings on the effect of PM-OP on systemic inflammation support that asthma is a heterogeneous disease at the molecular level, with PM-OP potentially playing an important role.

Indexed as

asthmainterleukin-6oxidative potential (OP)particulate matter (PM)systemic inflammation

Identifiers

PMID39765793
PMCPMC11673029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.